Inventor · disambiguated record
Zhengyi Wang
Also filed as: WANG ZHENGYI
19 granted patents·16 pending applications·55 citations·filing 2017–2024
92Inventor score
Files withI MAB BIOPHARMA US LTD16I MAB9I MAB BIOPHARMA CO LTD5CHINA RAILWAY ELEVENTH BUREAU GROUP CO LTD2BOSCH GMBH ROBERT1
Top patents by PatentIndex Score
35 records- 0195US10584169B2Anti-CD73 antibodies and uses thereofI MAB·Filed 2018·Granted Mar 10, 2020·11 cites·14 claims
- 0293US10059769B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2017·Granted Aug 28, 2018·15 cites·11 claims
- 0392US10208119B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2018·Granted Feb 19, 2019·11 cites·18 claims
- 0488US11034771B2Anti-CD73 anti-PD-L1 bispecific antibodiesI MAB BIOPHARMA US LTD·Filed 2019·Granted Jun 15, 2021·9 cites·23 claims
- 0584US10723799B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2018·Granted Jul 28, 2020·1 cites·18 claims
- 0682US11261259B2Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 1, 2022·1 cites·19 claims
- 0781US11926662B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA HANGZHOU CO LTD·Filed 2020·Granted Mar 12, 2024·1 cites·8 claims
- 0881US10577421B2Anti-LAG-3 antibodies and uses thereofI MAB·Filed 2018·Granted Mar 3, 2020·3 cites·11 claims
- 0979US11220546B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2019·Granted Jan 11, 2022·1 cites·19 claims
- 1073US11401331B2Anti-PD-L1 antibody and IL-7 fusionsI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 2, 2022·1 cites·6 claims
- 1172US10647767B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2017·Granted May 12, 2020·1 cites·22 claims
- 1267US11613577B2Anti-CD73 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 28, 2023·0 cites·8 claims
- 1367US2020317789A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 1466US2022119531A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 1565US12091467B2CD47 monoclonal antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Sep 17, 2024·0 cites·4 claims
- 1665US11414485B2Anti-LAG-3 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 16, 2022·0 cites·14 claims
- 1763US2025163150A1Combination therapies comprising a kras inhibitor for the treatment of cancerI MAB BIOPHARMA US LTD·Filed 2023·Application pending·0 cites
- 1862US2025304676A1A method of treating solid tumorL MAB BIOPHARMA US LTD·Filed 2023·Application pending·0 cites
- 1958US2025352645A1Biomarkers and methods for treating nsclcI MAB BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 2057US10889641B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2018·Granted Jan 12, 2021·0 cites·14 claims
- 2156US2020407441A1Fusion Proteins Containing CD48 Antibodies and CytokinesI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
- 2256US2020140565A1Novel cd47 monoclonal antibodies and uses thereofI MAB·Filed 2017·Application pending·0 cites
- 2355US2021095019A1Fusion Proteins Containing CD47 Antibodies and CytokinesI MAB·Filed 2018·Application pending·0 cites
- 2455US2023393144A1Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assaysI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 2554US2023399400A1Novel anti-cd47 antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2654US2023174649A1Pharmaceutical compositions containing anti-cd47 antibodiesI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 2752US2024209093A1Single domain pd-l1 antibodiesI MAB BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2851US11208486B2Human PD-L1 antibodiesI MAB BIOPHARMA US LTD·Filed 2020·Granted Dec 28, 2021·0 cites·18 claims
- 2951US10973853B2Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Apr 13, 2021·0 cites·7 claims
- 3051US2024078436A1Method and apparatus for generating training data for graph neural networkBOSCH GMBH ROBERT·Filed 2021·Application pending·0 cites
- 3150US12366679B2Method and device for identifying full-section excavation parameters of large-section tunnel with broken surrounding rockCHINA RAILWAY ELEVENTH BUREAU GROUP CO LTD·Filed 2024·Granted Jul 22, 2025·0 cites·10 claims
- 3250US2022112258A1Bifunctional molecules with il-7 activityI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 3349US2021269522A1Novel CD47 Antibodies and Methods of Using SameI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
- 3446US11920472B2Reasonable millisecond time control method for excavation blasting of tunnelCHINA RAILWAY ELEVENTH BUREAU GROUP CO LTD·Filed 2023·Granted Mar 5, 2024·0 cites·8 claims
- 3546US2019389972A1Modified ck and ch1 domainsI MAB·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhengyi Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →